Disease · MONDO_0004557

congenital fibrosarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. congenital fibrosarcoma. Diseases, record MONDO_0004557. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004557

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: congenital fibrosarcoma; Open Targets
Open Targets ID: MONDO_0004557; Open Targets
Other names: infantile fibrosarcoma, infantile fibrosarcoma (congenital fibrosarcoma), infantile fibrosarcoma (morphologic abnormality); Open Targets
Disease Ontology: DOID:8418; Disease Ontology
NCI Thesaurus: C4244; NCI Thesaurus
Highest stage of its drugs: Phase 2, for its one drug, from ClinicalTrials.gov; Open Targets

Drugs1

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here
LAROTRECTINIB	CHEMBL3889654	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3

Source Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NTRK1	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4914	Drugs and targets
NTRK2	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4915	Drugs and targets
NTRK3	Neurotrophic tyrosine kinase receptor	1	Neurotrophic tyrosine kinase receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4916	Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05236257	A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database		93	2024-12-10	Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma	LAROTRECTINIB	Its record names the disease	ClinicalTrials.gov
NCT03834961	Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia	Phase 2	33	2025-12-02	Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm	LAROTRECTINIB	Its record names the disease	ClinicalTrials.gov
NCT02637687	A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children	Phase 1/2	154		Solid Tumors Harboring NTRK Fusion	LAROTRECTINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Larotrectinib vs External Controls: deaths from any cause	1 of 51	3 of 42	93	NCT05236257	Trial comparisons
Larotrectinib vs External Controls: Number of Participants With Treatment Discontinuation Due to Treatment Emergent Adverse Events	0 of 51	1 of 42	93	NCT05236257	Trial comparisons
Larotrectinib vs External Controls: serious adverse events	1 of 51	3 of 42	93	NCT05236257	Trial comparisons

Papers from its trials20

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42614029	DERIVED	1	PubMed
40341199	DERIVED	1	PubMed
40267388	DERIVED	1	PubMed
39869835	DERIVED	1	PubMed
39652801	DERIVED	1	PubMed
38096907	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37769113	DERIVED	1	PubMed
37133249	DERIVED	1	PubMed
36689698	DERIVED	1	PubMed

1 to 10 of 20

See all 20 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004557

GET https://conductscience.org/api/diseases/v1/MONDO_0004557/drugs

API reference For AI assistants